Acetylsalicylic acid as an adjuvant therapy for schizophrenia.
BACKGROUND
Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.


METHODS
To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.
Laan
Wijnand
W
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. W.Laan@umcutrecht.nl
Selten
Jean-Paul
JP
Kahn
René S
RS
Huisman
Anne-Margriet
AM
Heijnen
Cobi J
CJ
Grobbee
Diederick E
DE
Burger
Huibert
H